Invention Grant
- Patent Title: Powerful MHC-class II peptides derived from survivin
- Patent Title (中): 强力的MHC-II类肽衍生自存活蛋白
-
Application No.: US12466222Application Date: 2009-05-14
-
Publication No.: US08647629B2Publication Date: 2014-02-11
- Inventor: Hans-Georg Rammensee , Stefan Stevanovic , Cécile Gouttefanges , Toni Weinschenk , Peter Lewandrowski
- Applicant: Hans-Georg Rammensee , Stefan Stevanovic , Cécile Gouttefanges , Toni Weinschenk , Peter Lewandrowski
- Applicant Address: DE Tuebingen
- Assignee: Immatics Biotechnologies GmbH
- Current Assignee: Immatics Biotechnologies GmbH
- Current Assignee Address: DE Tuebingen
- Agency: Miles & Stockbridge, P.C.
- Priority: EP08008944 20080514
- Main IPC: A61K38/08
- IPC: A61K38/08 ; A61K38/10 ; A61K39/00 ; C07K14/00 ; C12P21/00 ; A61K48/00
Abstract:
The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
Public/Granted literature
- US20100029571A1 NOVEL AND POWERFUL MHC-CLASS II PEPTIDES DERIVED FROM SURVIVIN Public/Granted day:2010-02-04
Information query
IPC分类:
